Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Edwards Lifesciences CFO to Step Down Amid Strong Q3 Results and Strategic Developments

Edwards Lifesciences, a leader in heart valve technologies, announced significant leadership changes and financial results, showcasing the company's resilience and growth in the cardiovascular medical device market.Edwards Lifesciences reported that CFO Scott Ullem will be stepping down from his position by mid-2026, after more than a decade of service. The company has initiated a process to select his successor, with Ullem transitioning to an advisory role after the appointment of a new CFO.

NoahAI News11/1/2025

Novo Nordisk's Bold Move: Challenging Pfizer's Metsera Acquisition

In a stunning turn of events, Novo Nordisk has made an unsolicited bid of $8.5 billion for Metsera, a rising star in the obesity and metabolic medicine space. This aggressive move comes just weeks after Pfizer had seemingly secured the acquisition of Metsera for nearly $5 billion, signaling a new era of fierce competition in the pharmaceutical industry.

NoahAI News11/1/2025

AbbVie's Immunology Portfolio Dominates Q3 Earnings, Signaling Shift from Humira Era

AbbVie's third-quarter financial results showcase the pharmaceutical giant's successful transition from its former blockbuster Humira to a new era dominated by its immunology duo, Skyrizi and Rinvoq. The company reported robust growth in its immunology sector, with these two drugs collectively generating nearly $7 billion in sales, accounting for almost half of AbbVie's quarterly revenue.

NoahAI News11/1/2025

Agilent Technologies Appoints New CFO Amid Ongoing Transformation

Agilent Technologies, a leading analytical and clinical laboratory business, has announced the appointment of Adam Elinoff as its new Chief Financial Officer (CFO). Elinoff, who brings 19 years of experience from biopharma giant Amgen, will assume his new role on November 17, 2023. This appointment fills the vacancy left by Bob McMahon, who resigned as CFO on July 31, 2023.

NoahAI News11/1/2025

Otsuka Pharmaceuticals Acquires Asia-Pacific Rights to 4DMT's Eye Disease Treatment for $85M Upfront

In a significant move within the ophthalmology sector, 4D Molecular Therapeutics has entered into a lucrative agreement with Japan's Otsuka Pharmaceuticals for the rights to develop and commercialize 4D-150, a novel eye disease treatment, in the Asia-Pacific region. The deal, announced on Thursday, includes an upfront payment of $85 million and could potentially reach over $400 million in total value.

NoahAI News11/1/2025

Eli Lilly Refines Pain Pipeline, Discontinues Mid-Stage P2X7 Inhibitor

Pharmaceutical giant Eli Lilly has announced another significant shift in its pain management pipeline, discontinuing development of a mid-stage P2X7 receptor inhibitor. This move comes as part of the company's ongoing efforts to refine its analgesic portfolio and focus on more promising candidates.

NoahAI News11/1/2025

Thermo Fisher Scientific to Acquire Clario Holdings in $9B Deal, Boosting Clinical Trial Technology Capabilities

Thermo Fisher Scientific, a leading life sciences company, has announced a significant acquisition that promises to reshape the landscape of clinical trial technology. In a deal valued at approximately $9 billion, Thermo Fisher will add Clario Holdings to its portfolio, enhancing its capabilities in clinical research services and data management.

NoahAI News11/1/2025

Lilly Reshapes Pain Drug Pipeline Amid Industry Challenges

Eli Lilly has quietly removed an experimental pain drug from its research pipeline, highlighting the ongoing challenges in developing effective treatments for chronic pain conditions. The pharmaceutical giant's decision underscores the complex landscape of pain management research and the high bar for success in this critical therapeutic area.

NoahAI News11/1/2025

AAP Declines to Recommend Leucovorin for Routine Autism Treatment Amid Ongoing Controversy

The American Academy of Pediatrics (AAP) has issued interim guidance stating that it does not recommend the routine use of leucovorin for children with autism, citing limited evidence. This announcement comes amid a complex and contentious debate surrounding autism treatments and potential links to common medications.

NoahAI News11/1/2025

Gilead's HIV Portfolio Drives Growth Amid Cell Therapy Challenges

Gilead Sciences reported a mixed bag of results in its third-quarter earnings, with its HIV franchise showing strong performance while cell therapy sales continue to decline. The California-based pharmaceutical company's total revenue increased by 3% compared to the same period last year, despite a 2% slide in overall product sales.

NoahAI News11/1/2025

Gilead's Q3 Earnings Reveal Growth in HIV Portfolio, Challenges in Other Areas

Gilead Sciences, a leading pharmaceutical company, has reported mixed results in its third-quarter earnings, showcasing strong performance in its HIV franchise while facing challenges in other areas. The company's strategic focus on dealmaking and expansion into new therapeutic areas highlights its commitment to growth and innovation in the pharmaceutical industry.

NoahAI News10/31/2025

Evommune Sets Sights on $160M IPO Amid Federal Shutdown

Evommune, a California-based biotech company, has announced its plans to raise up to $160 million through an initial public offering (IPO), joining the ranks of pharmaceutical firms going public in 2025. The company aims to list on the New York Stock Exchange under the ticker symbol EVMN, offering nearly 9.4 million shares priced between $15 and $17 each.

NoahAI News10/31/2025

1 2 3 4...67 »